In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICD-10 bill on the Hill

This article was originally published in The Gray Sheet

Executive Summary

House Ways & Means/Health Subcommittee approves markup May 24 of the "Health Information Technology Promotion Act of 2005" (HR 4157), including a provision that requires implementation of the next-generation ICD-10 Medicare coding system by Oct. 1, 2009. AdvaMed has sparred over the date with private payors such as the BlueCross BlueShield Association, which has urged Congress to postpone the switch until 2012 to allow time to prepare infrastructure (1"The Gray Sheet" May 22, 2006, p. 5). AdvaMed contends in a May 24 joint statement with hospital and medical information societies that "the current proposed October 2009 implementation deadline is long overdue....Only with a declared...deadline can the field begin to dedicate resources required to complete the detailed planning and development process." The device industry sees the limited number of codes in ICD-9 as an impediment to incorporating new technology into the reimbursement process. The bill now goes before the full Ways & Means Committee. If passed by the House it will go into conference with companion health IT bill S 1418...

You may also be interested in...

3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts